Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

By sjmartinez • April 11, 2025

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin Y, Xu H, Yu G, Mi Y, Fan Y, Wainberg ZA, Wang X, Su C, Yu Q, Lai S, Sun L, Zhuang W, Wang X, Yang J, Li Y, Ge J, Li J, Zhang L, Fang W. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638-2. Epub ahead of print. PMID: 40210967.

Tags: Hematology/Oncology, Publications

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown[...]

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program

Horwitz ME, Schiller GJ, Tsai SB, Rezvani AR, Maziarz RT, Goshen U, Levy S, Schwarzbach A, Mazor RD, Stiff PJ. Omidubicel-onlv Transplantation for Hematologic Malignancies:[...]

A Case of HIV-Associated Primary Central Nervous System Lymphoma Refractory to Methotrexate-Based Systemic Therapy and Immune Reconstitution

Cleveland JM, Cleveland HA, Chamberlain E, Sinclair J, Ku N, Schachter L, Di Carlo BA. A Case of HIV-Associated Primary Central Nervous System Lymphoma Refractory[...]